with a surprise new drug which treats multiple myeloma, blood cancer in the bailiwick of celgene. fda gave the drug the thumbs up which shocked people. coupled with the already proven celgene entry. that's one reason why the stock shot up like it did. the other is possible take over chatter since a wonder drug for the previously untreatable kidney and liver cancers has performed so wellment when you consider the endless rally, successful biotech has had going into and after fda approval i can see anybody voting for onxx. especially with regeneron. it's difficult to imagine onxx remaining independent but remember they have had a huge move already though cripolis is not a shoe-in to launch this year. that's important to point out. look, i know this is my show. i have the ego to prove it. but tonight i'm turning it over to you so you can vote on twitter @jimcramer for the homerun king for the second part of the year. that's the only reason why i'm putting, oh, boy, u.s. airways on the ballot. you heard me. u.s. airways. symbol lcc. not just because my flight on friday wasn't able to

and also celgene, that rumored -- celgene is a buy here still even though onyx's drug knocked it downter in california. accuray. aray. he wondered if it could be the next intuitive surgical. i wanted to do more homework before opining on this highly speculative medical device name that trades in the single digits. accuray acquired tomotherapy a year ago. they offer their cyber knife systems that deliver image guided therapy for the treatment of cancer and other diseases ranging from high precision radio surgery to precision guided radiation therapy. accuray announced the acquisition is go well while managers forecast a return to profitability in less than 12 months. but accuray is not the next -- everyone's always the next intuitive surgical. i'm concerned about government reimbursement rates from competition from varian medical which is a much large year player in the same space that's starting to gain traction internationally. this stock is up 56% for the year. so for heaven's sake ring the register. okay? i'm against greed. everyone's all excited again. believe me, you won't be exc

this company off, but confident the franchise remains intact and thriving and number of initiatives celgene earnings outside. given its stellar profits, much better than expected, it is an inexpensive stock with many years of growth ahead of it. i said that even after the stock went over $3. you know i like dividends, don't like expensive stocks. if anything, one particular drug prospect goes awry, but the three old biotech companies proved themselves time and time again, while they aren't for the feint of heart, you can get long-term growth that you can't get from a merck or pfizer or abbott labs. these companies are the risk takers, not afraid to make mistakes, innovate relentlessly, spend fortunes developing new drugs and remind me how the old-line pharmas used to be in the prepatent years. if that's not a big money to give gilead, amgen and celine a look, nothing is. stay with cramer. >>> a week ago, three down 100-point days. all i heard about was desperation. people pulled out of the market. no one believed anything good could happen. bingo, thursday, europe starts getting united abou

celgene. we want a fuller explanation of the set-back. we want the big numbers they talk about in the ad years. stock has been on the mend. i bet we'll be rewarded for staying with it. i'm worried about 3m. reports thursday. i normally wouldn't have trepidation. such a fabulous company. the stock's been on a tear. i fear it's gotten too much risk versus the strong dollar which i fear will play havoc with the quarter. be careful. there could be giveback. normally fridays are sleepy in the summer. nothing sleepy about chevron and merck. harvard is buying timber. you could do that. i own a couple of trees. my trust is buying weyerhauser. the stock isn't done yet. i'm a fan of dividends, but not merck. this attracts me even with slow growth. chevron gave us a rosy update that made my charitable trust a buy. no one else seemed to care. that's a mistake. it's cheap, steady with better growth than any major oil company including exxon. bottom line. another big one. another week with the u.s. in charge because there are so many report cards given

celgene reporting favorably of a drug application filing in the first half of 2013.pany. that's why the stock is up. look at okay me packet. a buy back of $200 million of its shares. over the next 12 months. lastly, i got one loser for you, green mountain coffee down 9.7%, falling after cutting the earnings estimates on the stock citing increased competition in the division and that's why that stock is down. back to you. >> thank you. >>> new numbers telling a familiar story. it's been a rough year for the video game sector. sales down significantly there in the past year, electronic arts is down 50%. take two interactive down 38%. activision, well, basically up 1.6%, roughly flat. julia boorstin is live in los angeles with more on the new data of the state of the industry. julia? >> reporter: well, tyler, june was another horrific month for video games. retail revenue plummeted 29% according to npd. console makers suffered the most, down 45 pstz last month of a year earlier and sales of the games dropped 29%. but according to npd, those suffering sales just about ha

take a look at celgene. the quarter and definitely something that analysts are excited about. amarin. fish oil pill. kind of an interesting story. tyler, over to you. >> thank you very much. >>> let's drill deeper on mario draghi's comment on doing whatever it takes to save the e euro to steve liesman. he said the same things before. why did today's comment resonate so much? >> you know, i think it was the context. i think it was all of the things he said all in one. yes, some of them before and maybe not altogether. i'll get to that in a second. they come after an ecb yesterday suggested that maybe they could give that european central -- european rescue fund a banking license to leverage up. it showed less opposition to that so that in context with draghi saying whatever it takes suggests that maybe the ecb is reducing the resistance to the all-out war that effectively waged by the federal reserve and ecb reluctant. now to do what it takes suggests there's more things to pull out of its, you know, bag of t

it is not dominated by amgen and celgene. >> how about nat gas?now if it is a surprise, some with what of under the radar move given everything else going on and so much of the focus in the energy space and take a look at nat gas pushing closer to $3 again. >> it is interesting. the first three months of the year nat gas fell 21%. i think you had short covering and buying going on and the buy we play it it through devan energy and i also like southwest energy and eog resources. they're all still very cheap. >> fears of acorn shortage sending futures higher. up together again as sweltering temperatures and droughts in the midwest are threatening crops and the commodities king joins us with his trade here. welcome to the show. good to have you. hope you had a good fourth, maybe ate corn on the cob or something. what's happening with corn? how are you trading it? >> you have to be long. it is amazing what's happening to the size of this crop. three weeks ago you would think we would have a record crop, maybe 14.7 billion bushels and the crop was in t

and celgene the other day reported better-than-expected -- >> enormous market cap biotechs.re the big guys. . we have a lot more stocks to watch after that opening bell. it's just three minutes away. stay with us. [ male announcer ] let's level the playing field. take the privileged investing tools of wall street and make them simple, intuitive, and available to all. distill all that data. make information instinctual, visual. introducing trade architect, td ameritrade's empowering web-based trading platform. take control of your portfolio today. trade commission-free for 60 days, and we'll throw in up to $600 when you open an account. >>> and the last trading session of the week begins. here at the big board, cohen and steers. over at the nasdaq, onboard. the big focus here, facebook hitting a fresh low in the session. $23.10 is the low in facebook. it looks like it's even challenging that at this point. >> may be too early to buy facebook. a la zynga and groupon. >> again, sarcasm. from cramer. >> i'm struggling -- that quarter, it took me an hour and a half to read the co